This technology describes a biomarker and its applications for diagnosing cancer and predicting its prognosis by utilizing changes in the galactosylation levels of serum-derived exosomes from cancer patients.
Existing cancer diagnostic methods have had limitations in early and precise diagnosis due to their low accuracy and specificity.
The biomarker developed with this technology demonstrates excellent specificity and sensitivity for cancer, thereby enhancing the accuracy of diagnosis and prognosis prediction for various cancer types and contributing to improved treatment efficacy.
N/A
